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Compounds possessing the ortho-dihydroxybenzene moiety 
and structurally related to levodopa and dopamine appear to 
belong to a new class of biologically active agents that are 
capable of inhibiting DNA synthesis in a variety of normal 
and malignant eukaryotic cells. They appear to work in part 
through their properties as potent reducing agents, and 
thereby interfere with several redox reactions that are crucial 
to the
' 
synthesis of cellular DNA. Interestingly, the com­
pounds can then be converted to their oxidized or quinone 
M elar. 10llu is a tumor whose increasing incidence, aggressive biologic behavior, and resistance to conventional antitumor agents have required the devC'lopment of new approaches to chemother­apy. Melanoma cells, in the majority of cases, re­
tain their ability to manufacture the pigment melanin, which is 
produced by the oxidation of amino-acid precursors. Specifically, 
tyrosine is converted to lcvodopa by tyrosinase which is uniquely 
found within melanocyte-derived cells. Levodopa is subsequently 
oxidized to melanin. Because this reaction occurs only within mela­
nocytes, and melanoma cells generally contain much more tyrosin­
ase than normal melanocytes, it might be possible to take advantage 
of this difference to design drugs that would be selectively toxic to 
melanoma cells. Potential agents would rely for their activity on the 
measurable phenotypic difference, melanin production, rather than 
on more-subtle growth differences between normal and malignant 
cells that conventional agents most often rely upon for selectivity. 
Furthermore, hecause the melanocyte serves a nonessential role in 
the host and cytotoxicity would be directed primarily against the 
melanocyte, it was envisioned that these drugs would be highly 
selective and relatively nontoxic. Most important, because these 
new agents have a novel mechanism of action, they would be ideal 
candidates for combination protocols with other conventional 
agents in the trt'atment of melanoma. 
Clinical Studies In developing this approach, over 60 analogs of 
lcvodopa and dopamine have been prepared and evaluated. The 
most promising of these is 3,4-dihydroxybenzylamine (3,4-DHBA) 
(NSC 263475), which is currently undergoing evaluation at the 
National Cancer IllStitute prior to introduction to clinical trial. 
Pcnding the availahility of new compounds, we were in a unique 
position of having hoth dopamine and levodopa availahle for study 
in clinical settings, although they were less effective in experimen­
tal systems. Levodopa, in particular, was an attractive candidate 
because of its ahility to cross the blood brain harrier, and CNS 
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forms, which are powerful electrophiles, and further disrupt 
cellular metabolism. This latter mechanism appears to ac­
count for the relatively increased cytotoxicity observed in 
melanin-producing cells, In addition to providing potential 
new agents for the treatment of advanced malignant mela­
noma, these compounds might prove to be valuable tools in 
determining the factors that influence rates of DNA synthe­
sis in normal and malignant cells.] . !l,vest DermatoI92:3295-
3315, 1989 
metastases involving melanoma continue to be a difficult therapeu­
tic problem. Dopamine had the advantage of being available for 
parenteral administration. 
Because there is currently no effective therapy for the treatment 
of advanced melanoma in humans, we sought to determine if cyto­
toxic levels could be achieved using dopamine, and if biochemical 
inhibitory effects on tumor cells in vivo as measured by thymidine 
incorporation, could be demonstrated. This is a prerequisite for a 
subsequent demonstration of an antitumor response [1]. 
Four patients with histologically proven metastatic malignant 
melanoma for whom no other treatment was available were ac­
cepted into the study. Patients were premedicated with propranolol, 
and dopamine infusions were maintained at maximally tolerable 
levels for 48 to 120 h, with constant monitoring of cardiovascular 
parameters. Bone-marrow aspirates were taken immediately prior 
to and 24 h after the initiation of therapy and processed for labeling 
and scintillation indices. Each patient had multiple cutaneous nod­
ules, which permitted excisional biopsy of the tumor and determi­
nation oflabeling index in the biopsy specimen before and 24 h after 
infusion was completed. Plasma levels were determined to assess 
whether or not they were in the tumoricidal range. 
Labeling and scintillation indices of the tumors were determined 
by a modification of reported techniques using single-cell suspen­
sions prepared from tumor biopsies. The mJjor toxicity was related 
to the cardiovascular effects of dopamine. At the maximally toler­
ated dose of 20 .ugjkg per min, steady-state plasma concentrations 
between 10-5 and 10-6 M were achieved. Comparison of the label­
ing index of the tumor, biopsied prior to the start of treatment and 
again 1 d after cessation of treatment, indicated a consistent tenfold 
reduction in labeling index. Bone-marrow samples processed before 
and 24 h after the start of infusion consistently showed a decrease in 
the incorporation of radioactively labeled nucleotide precursors, but 
no change in labeling index. 
The combination of levodopajcarbidopa was then used in an 
attempt to circumvent the toxicities of dopamine as well as to de­
liver the drug to the CNS [2]. Of 12 patients treated to date, eight 
are evaluable, and there have been four significant clinical re­
sponses. Significantly, the plasma levels achievable with levodopa 
were in tumoricidal range, as predicted by ill vitro assays (10-5 M). 
One patient had a complete resolution of a CNS lesion, as measured 
by a CAT scan, and a corresponding improvement in symptoms. 
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Pending the availability of improved analogs, further study of the 
use of levodopa/carbidopa as therapy for malignant melanoma in 
humans appears warranted. 
With the advent of dopamine analogs that are devoid of cardio­
vascular effects, the new drugs should be able to achieve the requi­
site concentrations in plasma without this dose limiting toxicity. 
Significantly, 3,4-dihydroxybenzylamine shows enhanced thera­
peutic activitv in all experimental models, primarily through an 
increase in the maximally tolerated dose. 
Mechanistic Studies Our recent efforts have focused upon the 
mechanistic processes underlying the remarkable selectivity that is 
exhibited by what are essentially members of a new class of anti pro­
liferative agents characterized by the possession of the ortho-dihy­
droxybenzene moiety. These efforts were preceded by studies that 
examined the effects of levodopa and closely related ortho-dihy­
droxybenzene derivatives on pigmented and nonpigmented clones 
of human melanoma cells growing in tissue culture. Levodopa itself 
has very little effect on cells that do not form pigment, but it appears 
to be highly inhibitory to the growth of pigment-producing cells. 
We extended these results to ill I'il'o systems using the B-16 mela­
noma in mice, as well as human melanomas transplanted into nude 
mice. We observed significant and reproducible antitumor activity 
in each of these systems, with a significant prolongation of survival 
of treated mice as compared with non treated controls [3,4]. 
In a typical experiment where mice bearing the B-16 melanoma 
were treated daily, the treated mice lived up to 50% longer than 
their non treated counterparts. In general, as far as can be predicted 
from preclinical studies, these results suggest that these antitumor 
drugs, although novel in structure, are at least as effective as con­
ventional antitumor drugs tested in these models. In addition, as a 
novel approach to chemotherapy, these derivatives offer unique 
opportunities to utilize both conventional and new approaches to 
combination chemotherapy. Thus, two groups have already begun 
to explore ways to enhance the antitumor effects of these com­
pounds. One approach by a group at Merrell Dow utilized difluoro­
methylornithine (which may lead to the induction of tyrosinase 
activity) in combination with 3,4-dihydroxybenzylamine. Their 
results showed that this combination resulted in a significant in­
crease in survival time of mice bearing the B16 melanoma [5]. A 
differmt approach by Meadow et al [6,7] utilizes alterations in diet, 
i.e., restricting levels of tyrosine and phenylalanine and/or addition 
of sodium ascorbate. They demonstrated that the antitumor effec­
tiveness of levodopa derivatives can be increased by controlling the 
animal's diet. 
Once the basic antitumor effects were established ill pirro and ill 
!li"o, we began to focus the mechanistic studies upon explaining the 
characteristic biochemical effects of the poly-hydroxybenzylamine 
compounds. Added impetus for the development of this line of 
investigation was given by the observation that the dihydroxyben­
zene derivatives were able to inhibit DNA synthesis in a variety of 
non-melanocyte-derived eukaryotic and prokaryotic cells, includ­
ing leukemia cells, squamous cell carcinoma, mushrooms, and bac­
teria. Our research in this area has led to an explanation of this 
gcnrral phrnomrnon that describes the ways in which the inhibi­
tory effects of the ortho-dihydroxybenzene compounds may differ 
between pigmented melanoma cells and nonpigmented cells. We 
havc discovered a possible difference in the inhibitory mechanism 
of action between various derivatives in different cell types, and we 
will review some of this evidence. 
The initial investigations with these drugs revealed that they 
inhibited thymidine incorporation ill pirro while having a minimal 
effect on RNA or protein synthesis [8]. The time course for the 
effect of 3,4-DHBA and dopamine upon thymidine incorporation 
indicated a rapid suppression of DNA synthesis (ca. 15 min follow­
ing exposure), which suggests the inhibition of a key reaction in 
DNA replication. The effect of these compounds on cell-cycle pro­
gression was analyzed by means of sequential DNA histograms 
using tlow cytotluorometry. The results demonstrate that the cells 
are arrested at the G1/S interface, suggesting a block in the metabo-
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lism of a precursor for DNA synthesis that prevents cells from 
entering the S phase. Finally, the survival curves from the clono­
genic assays are similar to drugs that are known inhibitors of DNA 
synthesis. These ill "irro findings suggested that the immediate cel­
lular effect of these catechols is a direct and selective inhibition of 
DNA synthesis. 
Inhibitors of DN A synthesis can be assigned to one of two classes: 
a) those that inhibit the supply of deoxyribonucleotides or b) those 
that directly interfere with the polymerase reaction, either by inhib­
iting the enzyme DNA polymerase or by altering the structure of 
the initiator-template. Using an isolated enzyme system as a model 
of a pigmented melanoma cell, we have been able to demonstrate 
that the dihydroxy derivatives of levodopa in the presence of the 
polyphenol oxidase, tyrosinase (which catalyzes the oxidation of 
tyrosine to melanin in melanocytes) are capable of inhibiting sulf­
hydryl-dependent DNA polymerases [9]. In this same study, we also 
described evidence for the molecular mechanism of action for 
tyrosinase activated 3,4-D HBA and obtained further evidence using 
preincubation, dialysis, and kinetic analyses, which confirmed that 
the inhibition of replication by oxidized 3,4-DHBA occurs at the 
level of DNA polymerase. This observation was extended by a Hill 
plot analysis which showed that there are two inhibitor sites in­
volved in the inactivation of the enzyme. Second, the inhibition of 
polymerase alpha by tyrosinase activated 3,4-DHBA is irreversible 
and cannot be restored by removal of the drug and addition of a 
reducing agent, e.g., dithioerythritol (DTE). This result, along 
with the demonstration that 3,4-DHBA tit rates the enzyme by 
reacting stoichiometrically, suggests that the inactivation involves 
the formation of a covalent bond, possible via a Michael addition of 
SH groups to the semiquinone species 3,4-DHBA. While earlier 
work suggested that inactivation of polymerase by quinols may be 
mediated by superoxide and hydroxyl-free radicals, it now appears 
more likely that inactivation is the result of direct titration of the 
enzyme by the drug and not a simple, indirect oxidation. Last, it was 
shown that DNA protects the enzyme, suggesting that the site of 
inhibition is at or near the active site [9]. 
The enzymes involved in the de IIO!'O production of DNA sub­
strates, deoxyribonucleotides, include several kinases, enzymes in­
volved in thymidylate synthesis, and ribonucleotide reductase. Ri­
bonucleotide reductase is considered to be the key enzyme for 
synthesis of dNTP, because it catalyzes not only a rate limiting step, 
but also the first step unique to DNA synthesis. This enzyme cata­
I yzes the one-step direct replacement of the 2'-0 H group of ribo­
nucleotide diphosphate with hydrogen. This reduction is accom­
plished by a radical dithiol system where the radical may involve a 
tyrosine residue with an unpaired electron at the hydroxyl group. 
Ribonucleotide reductase was a logical choice to pursue as a possible 
alternative or additional site of action for the ortho derivatives. 
Support for ribonucleotide reductase as a site of action of 3,4-DHBA 
has been presented by Elford et al [10], who demonstrated that 
reduced polyhydroxybenzene derivatives, including five levodopa 
analogs which we had been investigating, are potent inhibitors of 
isolated ribonucleotide reductase. We have been able to confirm and 
extend Elford's results using partially purified ribonucleotide reduc­
tase [11]. Our results showed that the inhibition of ribonucleotide 
reductase by 3,4-DHBA was reversible and competitive with the 
reducing substrate, DTE, i.e., the inhibitory activity was abolished 
at high DTE concentrations. 3,4-DHBA was not competitive 
toward the nucleotide diphosphate substrate. Hydroxyurea (HU), a 
known inhibitor of ribonucleotide reductase, has a partially compet­
itive relationship with the dithiol substrate, which suggests that 
these drugs do not inhibit ribonucleotide reductase by the same 
mechanism. To investigate this possibility, we examined the type of 
inhibitory interaction (synergistic, additive, or antagonistic) which 
results from combining these two inhibitors. An isobologram analy­
sis of the combined inhibitory effects of hydroxyurea and 3,4-
DHBA on ribonucleotide reductase suggested a synergistic interac­
tion [11]. This result agrees with the suggestion that 3,4-DHBA 
does not act at the same site as HU. 
The inhibitory elfect of several ortho-dihydroxybenzene deriva-
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tives on ribonucleotide reductase and DNA polymerase activity was 
examined using permeabilized cells. We were able to show that 
preincubation of cells with the drugs did not lead to increased inhi­
bition of ribonucleotide reductase. indicating that the inhibitory 
effect of the ortho-dihydroxybt'nzene derivatives was immediate. 
On the other hand. there was no immediate effect on DNA poly­
merase activity by these levodopa analogs. Inhibition of DNA poly­
merase was observed only after 1 h preincubation with the drugs 
[11 J. 
To describe further the action of these novel antitumor agents, 
we examined the action of these agents upon a third enzyme that is 
crucial to the control of DNA synthesis, thymidylate synthase. The 
ill pirro analysis of the effect of inhibitors of the various enzymes 
involved in DNA synthesis is made difficult because the cell mem­
brane is impermeable to their immediate substrates. The use of 
permeabilized cells is one technique that we have used to circum­
vent this problem. An alternative itl situ approach for the study of 
the enzyme thymidylate synthase has been developed which utilizes 
charcoal filtration to isolate [3H]-H20 released from [5-3H] deoxy­
uridylate. The initial studies were designed to determine the effects 
of the antitumor agents bearing the dihydroxybenzene moiety upon 
thymidylate synthase activity ill situ [12,13]. Significant inhibition 
of thymidylate synthase was observed with each of the ortho-dihy­
droxybenzene analogs with 3,4-DHBA showing the greatest inhib­
itory activity (ICso 176 .uM). We examined the inhibitory effect of 
3,4-DHBA on the enzyme's activity using a partially purified cell­
free extract to determine if the observed inhibitory effect upon 
thymidylate synthast' was directly or indirectly mediated. Similar to 
the findings of Reddy and Pardee [14], who examined the effects of 
the ribonucleotide reductase inhibitor, hydroxyurea, on thymidy­
late synthase, we also found that while the catechols had an inhibi­
tory effect on thymidylate synthase ill sitll, they had no inhibitory 
effect against the isolated enzyme. This result suggests that the ill 
siw inhibitory effect involves an indirect mechanism. One possible 
indirect mechanism is that the quinol must be activated, oxidized to 
the quinone form, before it is capable of inhibiting thymidylate 
synthase. We were able to show that the oxidized form of 3,4-
DHBA is a very potent irreversible inhibitor of this enzyme 
(ICso < IOO.uM). However, in the nonpigmented cell lines used in 
the thymidylate synthase studies, the ill sitll inhibition of this en­
zyme was found to be reversible. Another possible indirect mecha­
nism invokes the concept of the replitase, the putative multienzyme 
complex for the synthesis of DNA [14]. Thus, a drug may directly 
affect one enzyme of this complex (e.g., 3,4-DHBA inhibits ribo­
nucleotide reductase) which leads, as the result of allosteric interac­
tions, to the indirect inhibition of other enzyme(s) of the replitase, 
e.g., thymidylate synthase. 
The dihydroxybenzene derivatives related to levodopa and dopa­
mine have been shown to inhibit three enzymes related to DNA 
synthesis ribonucleotide reductase, DNA polymerase, and thymi­
dylate synthase. From our results using the permeabilized cell tech­
nique and from our ill sitll assays, it would appear that the most 
likely initial event is the inhibition of ribonucleotide reductase. If 
the inhibition of ribonucleotide reductase is sufficient, perhaps re­
sulting in a reduction in deoxynucleotide pools below a critical 
threshold level, then the inhibition of DNA synthesis is immediate. 
Our results appear to indicate that 3,4-DHBA need not inhibit 
ribonucleotide reductase completely in order to totally suppress 
DNA synthesis. At lower concentrations of 3,4-DHBA, the inhibi­
tory effect on DNA synthesis is delayed (ca. 15 min at 0.2 mM), 
possibly until the deoxynucleotide pools are sufficiently reduced. In 
contrast, the inhibition of thymidylate synthase is delayed regard­
less of the drug concentration for about 20 min. The inhibition of 
DNA polymerase is also delayed at each of the drug concentrations 
[11 J. The time of onset of inhibition of these two enzymes docs not 
correlate with the time of onset of inhibition of DNA synthesis, 
w hnea'> the time of onset of inhibition of ribonucleotide reducta'>c 
either coincides or precedes the inhibition of DNA synthesis. One 
possible explanation for the delayed inhibitory eifecr on DNA poly­
merase and thymidylate synthase is that the drug must be activated 
to the quinone in order to inhibit these enzymes. We have pre­
viously shown that the oxidized form is a very potent inhibitor of 
DNA polymerase [9] and that the quinone is also a very potent 
inhibitor of thymidylate synthase [12J. In cells of high oxidative 
potential, e.g., melanoma, this quinone mediated mechanism might 
be uniquely important. 
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